+
AstraZeneca India To Sell 64-Acre Bengaluru Facility
Real Estate

AstraZeneca India To Sell 64-Acre Bengaluru Facility

AstraZeneca India is set to divest its 64-acre production facility in North Bengaluru as part of a global reassessment of its manufacturing and supply chain operations. This initiative aligns with the parent company’s broader strategy to optimise resources through corporate land monetization. 

According to the reports in the media, the proposed transaction is estimated to bring in over Rs 32 billion. AstraZeneca has reportedly engaged global property consultants to identify potential buyers for the land, which is valued at more than Rs 500 million per acre. Despite previous attempts to sell, the high valuation had posed challenges in securing a deal. 

The company intends to transfer the facility as a fully operational unit and is actively searching for a buyer who can also serve as a contract manufacturing organization (CMO) to continue its existing production and packaging operations, subject to necessary approvals. 

A key part of AstraZeneca Pharma’s global network, the Bengaluru facility is one of nine sites dedicated to clinical trial design and execution. The planned sale underscores AstraZeneca’s broader strategic shift to streamline global operations while maintaining critical pharmaceutical production through external partnerships. 

AstraZeneca India is set to divest its 64-acre production facility in North Bengaluru as part of a global reassessment of its manufacturing and supply chain operations. This initiative aligns with the parent company’s broader strategy to optimise resources through corporate land monetization. According to the reports in the media, the proposed transaction is estimated to bring in over Rs 32 billion. AstraZeneca has reportedly engaged global property consultants to identify potential buyers for the land, which is valued at more than Rs 500 million per acre. Despite previous attempts to sell, the high valuation had posed challenges in securing a deal. The company intends to transfer the facility as a fully operational unit and is actively searching for a buyer who can also serve as a contract manufacturing organization (CMO) to continue its existing production and packaging operations, subject to necessary approvals. A key part of AstraZeneca Pharma’s global network, the Bengaluru facility is one of nine sites dedicated to clinical trial design and execution. The planned sale underscores AstraZeneca’s broader strategic shift to streamline global operations while maintaining critical pharmaceutical production through external partnerships. 

Next Story
Infrastructure Transport

Syama Prasad Mookerjee Port Partners to Redevelop Nimtala Ghat

Kolkata: Syama Prasad Mookerjee Port, Kolkata (SMPK), signed a Memorandum of Understanding (MoU) on Tuesday with PS Group Realty Private Limited to redevelop and beautify Nimtala Ghat as part of PS Group’s Corporate Social Responsibility (CSR) initiative.The agreement was formalised at SMPK’s Head Office at 15, Strand Road, in the presence of SMPK chairman Rathendra Raman, deputy chairman Samrat Rahi, PS Group directors Saurav Dugar, Gaurav Dugar, Arun Sancheti, and senior SMPK officials.Under the MoU, PS Group will undertake the full redevelopment and permitted construction of Nimtala Imm..

Next Story
Infrastructure Urban

CSIR-NCL and Covestro Collaborate to Upcycle Polyurethane Waste

In a move towards sustainable plastic waste management, Pune-based CSIR-National Chemical Laboratory (CSIR-NCL) signed a Memorandum of Understanding (MoU) with Covestro (India) Private Limited on Wednesday to develop innovative upcycling technologies for polyurethane waste.Polyurethane is notoriously difficult to recycle, with current methods often proving inefficient, costly, and environmentally harmful. This collaboration aims to address existing challenges, including high energy usage and deterioration of material quality during recycling.Ashish Lele, director of CSIR-NCL, stated, “This p..

Next Story
Infrastructure Urban

Torrent Pharma Seeks CCI Approval for Rs 195 Billion JB Chemicals Deal

Ahmedabad-based Torrent Pharmaceuticals has sought clearance from the Competition Commission of India (CCI) to acquire a majority stake in J B Chemicals and Pharmaceuticals in a Rs 195 billion deal.Upon completion, Torrent Pharmaceuticals will become India’s second most valuable pharmaceutical company.The move follows Torrent’s June announcement to acquire a majority stake in J B Chemicals for Rs 195 billion.“The proposed combination pertains to the acquisition of shareholding by Torrent Pharmaceuticals Ltd in J B Chemicals & Pharmaceuticals Ltd, followed by the merger of the target ..

Advertisement

Subscribe to Our Newsletter

Get daily newsletters around different themes from Construction world.

STAY CONNECTED

Advertisement

Advertisement

Advertisement

Talk to us?